Immune cell engagers (ICEs) are becoming increasingly significant in the field of immuno-oncology due to their ability to harness the body's immune system to target and destroy cancer cells. Since the approval of the first bispecific T-cell engager (BiTE), Blinatumomab, in 2014, the field has seen rapid advancements. Newer generations of ICEs, including trispecific antibodies and NK cell engagers, are being developed to enhance their efficacy and broaden their application to various types of cancers. Genentech has developed a NKG2D-HER2 ICE which enhances NK and CD8+ T-cell antitumor immunity. Read our recent article to learn more about how Evotec Immunology team collaborated with Genentech teams and co-authored this article by bringing Immunological Synapse expertise for strengthening Genentech ICE characterization.